Researchers in the Neuromuscular Disorder-Chip Consortium will use custom-designed NimbleGen Human CGH 12x135K microarrays and Human Sequence Capture 385K arrays to study the genetic underpinnings of a range of neuromuscular disorders.
The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.
Chronix Biomedical said that the current study confirms its previous research showing that CNAs can identify the presence of certain diseases in blood samples months to years before clinical symptoms appear.
A European research team has developed an approach that uses information about positional weight matrices, comparative genomics, and gene expression profiling to find Stat3 transcription factor binding sites in the mouse genome.
Applied Biosystems and TGen will collaborate on translational genomic disease studies employing the SOLiD 3 system. The partners also hope to drive down the cost of genome sequencing so that it can ultimately be used as a routine diagnostic tool.
Under terms of the deal, Novartis will give Epistem a $4 million upfront payment and provide funding to study the stem cell shop's drug targets. Epistem could also get up to $45 million in milestone payments for each product developed from targets licensed under the agreement.